An interventional study of in vitro maturation (IVM) of oocytes in PCOS (Polycystic Ovary Syndrome), sponsored by Hospital St. Joseph, Marseille, France. Recruiting at 1 site in France. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Hospital St. Joseph, Marseille, France · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Polycystic Ovary Syndrome with a site in France — 9 open to participants now, 10 under way, 1 of them phase 3. Polycystic Ovary Syndrome · France.
Among the 21 studies in Polycystic Ovary Syndrome with a site in France, this one is the 11th largest by planned enrollment of the 13 interventional ones that give a count, is one of 5 that started in 2026, is one of 8 with no phase, and was the 21st registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →9 of the 21 studies in Polycystic Ovary Syndrome with a site in France are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–45 · Women only
Centre Hospitalier Universitaire, Amiens · Sites in France
Ages 18+ · Women only
University Hospital, Strasbourg, France · Sites in France
Ages 18–49
CHU de Reims · Sites in France
Ages 18–45 · Women only
University Hospital, Clermont-Ferrand · Sites in France
Ages 18–43 · Women only
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 37 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 70 across 700 interventional studies indexed under Polycystic Ovary Syndrome.
Median enrollment 52 across the 13 interventional studies, 100 across the 8 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 21 have an industry lead sponsor. The 10 most frequent:
Hospital St. Joseph, Marseille, France is the lead sponsor of 33 studies on the registry; 6 are open to participants now.
Hospital St. Joseph, Marseille, France has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
4 of the studies in Polycystic Ovary Syndrome with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03059173Phase 3University Hospital, LilleInterest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome | 2027-09-12 |
| NCT07016035CHU de ReimsTranslation and Validation of the French mPCOSQ (mPCOSQ-F). | 2027-05-12 |
| NCT07499518Assistance Publique - Hôpitaux de ParisFertility and Polycystic Ovary Syndrome | 2027-06-01 |
| NCT07483723Centre Hospitalier Universitaire, AmiensGlucose Profiles in Women With Polycystic Ovary Syndrome | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 21 studies in Polycystic Ovary Syndrome with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The OPKAPAMIV study is a monocentric, open-label clinical trial evaluating the effectiveness of CAPA-MEDIUM culture medium for in vitro maturation (IVM) of oocytes in women with polycystic ovary syndrome (PCOS) undergoing assisted reproductive technology. The primary objective is to achieve a 60% maturation rate of immature cumulus-oocyte complexes (COCs) retrieved from PCOS patients. Secondary objectives include assessing fertilization, blastulation, implantation, pregnancy, and live birth rates, as well as monitoring the health of children born from these procedures. The study also compares outcomes between fresh and vitrified oocytes. The protocol aims to improve safety and success rates for PCOS patients, reducing the risk of ovarian hyperstimulation syndrome by avoiding conventional ovarian stimulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: in vitro maturation (IVM) of oocytes
In Vitro Maturation (IVM) Protocol Phase 1 (CAPA-medium): The cumulus-oocyte complexes (COCs) are incubated for 24 hours in an enriched medium (CAPA-medium) containing HSA, insulin, estradiol, FSH, amphiregulin, and CNP, mimicking the natural follicular environment. Phase 2 (IVM-medium): After 24 hours, the COCs are transferred into another medium (IVM-medium) for an additional 30 hours, promoting both nuclear and cytoplasmic maturation.
Oocyte Maturation Rate = Number of MII oocytes / Number of COCs retrieved, compared to published data on conventional IVM for similar maternal age and PCOS indications.
Time frame: From enrollement to 56 hours after the end of treatrment
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Oct 2028, 29 months after the start.
Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 29 months is above that.
Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital St. Joseph, Marseille, France